Tobacco and Nicotine: Cash Flows and Next-Gen Products

Introduction

Few consumer businesses lose a tenth of their volume in a year and keep generating as much cash. Altria, the maker of Marlboro in the US, reported that its domestic cigarette shipments fell to 61.8 billion units in 2025, a decrease of 10.0%, as smokers quit, switched to other nicotine products or bought illicit flavored vapes. Yet cigarette companies remain among the most cash-generative businesses in consumer goods, because they raise prices faster than volumes fall.

That combination, pricing power on declining volumes, defines the traditional tobacco business. The industry's future rests on next-generation products: heated tobacco, e-vapor and nicotine pouches that deliver nicotine without burning tobacco. How quickly companies can shift their profits to these products, under tight regulation, decides their value and drives their deals.

Cigarettes are a mature, heavily taxed and heavily regulated product, but they have unusual economics. Consumers are loyal to their brands, the product is addictive, and new competitors face severe limits on advertising, so a handful of companies control most of the market in each country. In the US, Altria and Reynolds American, owned by British American Tobacco (BAT), dominate; internationally, PMI, BAT, Japan Tobacco International and Imperial Brands lead, alongside state-owned monopolies such as China's. This market concentration and brand loyalty underpin everything that follows.

Price over volume

The core of the model is annual price increases. Because demand is inelastic, a price rise loses fewer smokers than it gains in revenue per pack, so the cigarette business can shrink in units while its revenue and profit stay roughly flat. It is the extreme case of the dynamic described in the article on brand equity and pricing power.

Taxes and settlement payments

Much of the price of a pack goes to governments. The federal excise tax on cigarettes is about $1.01 a pack, and state excise taxes range from modest to several dollars more, with some cities adding their own. US manufacturers also make annual settlement payments under the 1998 tobacco settlement with the states.

Master Settlement Agreement (MSA)

The 1998 agreement between the largest US cigarette manufacturers and 46 states, along with several territories, that settled state lawsuits over smoking-related health costs. In exchange for releases from those claims, the manufacturers agreed to make annual payments to the states indefinitely and to accept restrictions on marketing, with the payments adjusted for volume and inflation.

Taxes and settlement costs add to the price shoppers pay and make cigarettes sensitive to tax increases: a large excise rise can push some smokers to quit, switch or buy untaxed products. Altria's own filings note that settlement payments have contributed to substantial cigarette price increases over time.

Cash flow and capital returns

With little need for new plants and stable working capital, tobacco companies convert most of their earnings into free cash flow. They return much of it to shareholders through dividends, which is why tobacco stocks are held largely for income, and they carry meaningful debt. The main threat to that cash is not a recession but the pace of decline: if volume losses accelerate faster than prices can rise, as illicit vapes caused in parts of the US market, the cushion thins and earnings start to fall. The resilience of this demand through economic cycles is part of why tobacco is classed as a staple, as explained in the article on staples versus discretionary demand.

The industry's long-term challenge is that cigarette volumes in developed markets keep falling. The large companies are trying to replace them with reduced-risk products that deliver nicotine with fewer harmful constituents and that regulators may allow to be marketed as alternatives to smoking. Most of these products, like cigarettes, are sold through convenience stores, where tobacco and nicotine remain a major source of traffic and profit, as the article on convenience stores explains.

Three categories of alternatives

Philip Morris International (PMI) has gone furthest. Smoke-free products accounted for nearly $17 billion, or 41.5%, of its more than $40 billion of 2025 net revenues, and its US ZYN shipments reached 794 million cans for the year. Altria, which sells Marlboro only in the US since PMI was spun off in 2008, bought the e-vapor company NJOY in 2023 and sells its own nicotine pouches, but its business still depends far more on cigarettes.

Regulatory approval as the gate

In the US, new tobacco products need marketing authorization from the Food and Drug Administration's Center for Tobacco Products before they can be sold.

Premarket Tobacco Product Application (PMTA)

The application a company must submit to the US Food and Drug Administration to market a new tobacco or nicotine product, showing that allowing the product would be appropriate for the protection of public health. The FDA weighs risks and benefits to the population as a whole, including effects on smokers who might switch and on non-users, especially young people, who might start.

The FDA issued its first marketing orders for nicotine pouches in January 2025, authorizing 20 ZYN products after finding they contain substantially lower amounts of harmful constituents than cigarettes and most smokeless tobacco. The agency stressed that the authorization does not mean the products are safe or "FDA approved". Authorization is a major competitive advantage, because unauthorized products can be removed from the market, but enforcement against illicit vapes has been uneven, which has let unauthorized disposable products take share from both cigarettes and authorized alternatives.

Tobacco carries risks that few consumer categories face:

These factors weigh on valuations. Tobacco companies typically trade at lower multiples than other staples despite their cash flows, and the market rewards companies that can show a credible path from cigarettes to next-generation products.

Tobacco deals follow from the transition away from cigarettes. The largest groups buy next-generation businesses to accelerate it, and they finance those purchases with the cash and debt capacity their cigarette businesses provide:

PMI paid about $16 billion for Swedish Match, a premium that rested almost entirely on the expected growth of nicotine pouches in the US. Companies also defend their cigarette cash flows through cost cutting and pricing, and some have sold regional or discount brands to smaller specialists that focus on running declining brands for cash.

For bankers, tobacco is a niche but meaningful part of consumer coverage. Mandates include financings for highly cash-generative companies, acquisitions of next-generation brands and sales of regional or legacy cigarette brands. The analysis always comes back to two questions: how long the cigarette cash flows can last as volumes fall, and how much of that cash the company can turn into durable next-generation profit. The wider set of staples deals, and how buyers think about portfolio transitions, is covered in the article on staples M&A.